A cross-sectional study for glucose intolerance of myotonic dystrophy

Journal of the Neurological Sciences

Volumn 276, Issue 1-2, 2009, Pages 60-65

  Matsumura, Tsuyoshi ^a   Iwahashi, Hiromi ^b   Funahashi, Tohru ^b   Takahashi, Masanori P ^b   Saito, Tomoko ^a   Yasui, Kumiko ^a   Saito, Toshio ^a   Iyama, Akinori ^a   Toyooka, Keiko ^a   Fujimura, Harutoshi ^a   Shinno, Susumu ^a  

^a TONEYAMA NATIONAL HOSPITAL   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Adiponectin; Glucose intolerance; Hyperinsulinemia; Hyperlipemia; Insulin resistance; Myotonic dystrophy

Indexed keywords

ADIPONECTIN; CHOLESTEROL; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SUGAR; TRIACYLGLYCEROL;

ADULT; AGE; ARTICLE; BLOOD CHEMISTRY; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CONTROL GROUP; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DIET RESTRICTION; DISEASE PREDISPOSITION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; HEMOGLOBIN BLOOD LEVEL; HOMEOSTASIS MODEL ASSESSMENT INSULIN RESISTANCE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; MYOTONIA; MYOTONIC DYSTROPHY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ANALYSIS OF VARIANCE; BLOOD GLUCOSE; CROSS-SECTIONAL STUDIES; FEMALE; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; MYOTONIC DYSTROPHY; STATISTICS, NONPARAMETRIC;

EID: 58149159858     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2008.08.037     Document Type: Article

References (46)

1. Brook J.D., McCurrach M.E., Harley H.G., Buckler A.J., Church D., Aburatani H., et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member. Cell 68 (1992) 799-808
2. Harper P. Myotonic dystrophy. 3rd ed. (2001), Saunders WB, London
3. Osborne R.J., and Thornton C.A. RNA-dominant diseases. Hum Mol Genet 15 (2006) R162-169 Spec No 2
4. Miller J.W., Urbinati C.R., Teng-Umnuay P., Stenberg M.G., Byrne B.J., Thornton C.A., et al. Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy. Embo J 19 (2000) 4439-4448
5. Lin X., Miller J.W., Mankodi A., Kanadia R.N., Yuan Y., Moxley R.T., et al. Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy. Hum Mol Genet 15 (2006) 2087-2097
6. Philips A.V., Timchenko L.T., and Cooper T.A. Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy. Science 280 (1998) 737-741
7. Mankodi A., Takahashi M.P., Jiang H., Beck C.L., Bowers W.J., Moxley R.T., et al. Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. Mol Cell 10 (2002) 35-44
8. Kimura T., Takahashi M.P., Okuda Y., Kaido M., Fujimura H., Yanagihara T., et al. The expression of ion channel mRNAs in skeletal muscles from patients with myotonic muscular dystrophy. Neurosci Lett 295 (2000) 93-96
9. Moxley III R.T., Griggs R.C., Goldblatt D., VanGelder V., Herr B.E., and Thiel R. Decreased insulin sensitivity of forearm muscle in myotonic dystrophy. J Clin Invest 62 (1978) 857-867
10. Perseghin G., Caumo A., Arcelloni C., Benedini S., Lanzi R., Pagliato E., et al. Contribution of abnormal insulin secretion and insulin resistance to the pathogenesis of type 2 diabetes in myotonic dystrophy. Diabetes Care 26 (2003) 2112-2118
11. Annane D., Duboc D., Mazoyer B., Merlet P., Fiorelli M., Eymard B., et al. Correlation between decreased myocardial glucose phosphorylation and the DNA mutation size in myotonic dystrophy. Circulation 90 (1994) 2629-2634
12. Vlachopapadopoulou E., Zachwieja J.J., Gertner J.M., Manzione D., Bier D.M., Matthews D.E., et al. Metabolic and clinical response to recombinant human insulin-like growth factor I in myotonic dystrophy-a clinical research center study. J Clin Endocrinol Metab 80 (1995) 3715-3723
13. Kono S. Insulin resistance in myotonic dystrophy. Nippon Rinsho 60 (2002) 734-738
14. Savkur R.S., Philips A.V., and Cooper T.A. Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat Genet 29 (2001) 40-47
15. Guiraud-Dogan C., Huguet A., Gomes-Pereira M., Brisson E., Bassez G., Junien C., et al. DM1 CTG expansions affect insulin receptor isoforms expression in various tissues of transgenic mice. Biochim Biophys Acta 1772 (2007) 1183-1191
16. Llagostera E., Catalucci D., Marti L., Liesa M., Camps M., Ciaraldi T.P., et al. Role of myotonic dystrophy protein kinase (DMPK) in glucose homeostasis and muscle insulin action. PLoS ONE 2 (2007) e1134
17. Barreca T., Muratorio A., Sannia A., Murri L., Rossi B., and Rolandi E. Evaluation of twenty-four-hour secretory patterns of growth hormone and insulin in patients with myotonic dystrophy. J Clin Endocrinol Metab 51 (1980) 1089-1092
18. Okimura Y., Chihara K., Kita T., Kashio Y., Sato M., Kitajima N., et al. Discordance between growth hormone (GH) responses after GH-releasing hormone and insulin hypoglycemia in myotonic dystrophy. J Clin Endocrinol Metab 67 (1988) 1074-1079
19. Fernandez-Real J.M., Molina A., Broch M., Ricart W., Gutierrez C., Casamitjana R., et al. Tumor necrosis factor system activity is associated with insulin resistance and dyslipidemia in myotonic dystrophy. Diabetes 48 (1999) 1108-1112
20. Johansson A., Carlstrom K., Ahren B., Cederquist K., Krylborg E., Forsberg H., et al. Abnormal cytokine and adrenocortical hormone regulation in myotonic dystrophy. J Clin Endocrinol Metab 85 (2000) 3169-3176
21. Johansson A., Ahren B., Forsberg H., and Olsson T. Testosterone and diurnal rhythmicity of leptin, TNF-alpha and TNF-II receptor in insulin-resistant myotonic dystrophy patients. Int J Obes Relat Metab Disord 26 (2002) 1386-1392
22. Johansson A., Olsson T., Cederquist K., Forsberg H., Holst J.J., Seckl J.R., et al. Abnormal release of incretins and cortisol after oral glucose in subjects with insulin-resistant myotonic dystrophy. Eur J Endocrinol 146 (2002) 397-405
23. Yamanouchi K., Shinozaki T., Chikada K., Nishikawa T., Ito K., Shimizu S., et al. Daily walking combined with diet therapy is a useful means for obese NIDDM patients not only to reduce body weight but also to improve insulin sensitivity. Diabetes Care 18 (1995) 775-778
24. Nakai N., Shimomura Y., Ohsaki N., Sato J., Oshida Y., Ohsawa I., et al. Exercise training prevents maturation-induced decrease in insulin sensitivity. J Appl Physiol 80 (1996) 1963-1967
25. Zinman B., Ruderman N., Campaigne B.N., Devlin J.T., and Schneider S.H. Physical activity/exercise and diabetes mellitus. Diabetes Care 26 (2003) S73-77 Suppl 1
26. Lue Y.J., Su C.Y., Yang R.C., Su W.L., Lu Y.M., Lin R.F., et al. Development and validation of a muscular dystrophy-specific functional rating scale. Clin Rehabil 20 (2006) 804-817
27. Nagaretani H., Nakamura T., Funahashi T., Kotani K., Miyanaga M., Tokunaga K., et al. Visceral fat is a major contributor for multiple risk factor clustering in Japanese men with impaired glucose tolerance. Diabetes Care 24 (2001) 2127-2133
28. Mellitus TcoJDSftdcod. Report of the committee of Japan Diabetes Society on the classification and diagnostic criteria of diabetes mellitus. J Jpn Diab Soc 42 (1999) 385-404
29. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
30. Bonora E., Moghetti P., Zancanaro C., Cigolini M., Querena M., Cacciatori V., et al. Estimates of in vivo insulin action in man: comparison of insulin tolerance tests with euglycemic and hyperglycemic glucose clamp studies. J Clin Endocrinol Metab 68 (1989) 374-378
31. Yoshizumi T., Nakamura T., Takahashi M., Funahashi T., Yamashita S., Matsuzawa Y., et al. To diffuse assessment tool for evaluation of abdominal visceral fat with computed tomography -establishment of conditions for computed tomography and development of computer software-(Japanese, author translated). Himan Kenkyu 6 (2000) 193-199
32. Bottner A., Kratzsch J., Muller G., Kapellen T.M., Bluher S., Keller E., et al. Gender differences of adiponectin levels develop during the progression of puberty and are related to serum androgen levels. J Clin Endocrinol Metab 89 (2004) 4053-4061
33. Bonora E., Targher G., Alberiche M., Bonadonna R.C., Saggiani F., Zenere M.B., et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 23 (2000) 57-63
34. Tanaka H., Matsumura T., Saito T., Iyama A., Miyashita N., Fujikawa R., et al. Arteriosclerosis in myotonid dystrophy--(Japanese, Author translated) (2005), The Research Grant for Nervous and Mental Disorders (14A-5) from Ministry of Health, Labour and Welfare, Tokyo
35. Maeda N., Shimomura I., Kishida K., Nishizawa H., Matsuda M., Nagaretani H., et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8 (2002) 731-737
36. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257 (1999) 79-83
37. Adamczak M., Wiecek A., Funahashi T., Chudek J., Kokot F., and Matsuzawa Y. Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 16 (2003) 72-75
38. Ouchi N., Kihara S., Arita Y., Maeda K., Kuriyama H., Okamoto Y., et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100 (1999) 2473-2476
39. Zoccali C., Mallamaci F., Panuccio V., Tripepi G., Cutrupi S., Parlongo S., et al. Adiponectin is markedly increased in patients with nephrotic syndrome and is related to metabolic risk factors. Kidney Int Suppl (2003) S98-102
40. Nishizawa H., Shimomura I., Kishida K., Maeda N., Kuriyama H., Nagaretani H., et al. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 51 (2002) 2734-2741
41. Tamura T., Furukawa Y., Taniguchi R., Sato Y., Ono K., Horiuchi H., et al. Serum adiponectin level as an independent predictor of mortality in patients with congestive heart failure. Circ J 71 (2007) 623-630
42. Yasui T., Tomita J., Miyatani Y., Yamada M., Uemura H., Irahara M., et al. Associations of adiponectin with sex hormone-binding globulin levels in aging male and female populations. Clin Chim Acta 386 (2007) 69-75
43. Chiasson J.L., Josse R.G., Gomis R., Hanefeld M., Karasik A., and Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. Jama 290 (2003) 486-494
44. Iwahashi H., Marukawa S., Matsumoto Y., Imagawa A., Fukui K., Sayama K., et al. Insulin resistance in myotonic dystrophy can be improved by pioglitazone but not buformin. Diabetes J. 31 (2003) 92-96
45. Yamamoto T., Oya Y., Isobe T., Shirafuji T., Ogata K., Ogawa M., et al. Long-term treatment of diabetes mellitus in myotonic dystrophy with pioglitazone. Rinsho Shinkeigaku 45 (2005)
46. Kouki T., Takasu N., Nakachi A., Tamanaha T., Komiya I., and Tawata M. Low-dose metformin improves hyperglycaemia related to myotonic dystrophy. Diabet Med 22 (2005) 346-347